This is not yet the signal for the complete abandonment of the use of chloroquine or hydroxychloroquine (HCQ) against Covid-19, but it is more and more like it. The study published on May 22 in the leading scientific journal The Lancet should appeal to those who, like US President Donald Trump, still think that if it does not do good, in any case it cannot do harm!
Read also: Chloroquine: where are the trials?
The authors, led by Professor Mandeep Mehra of Harvard, however, take care not to strike anyone in the summary of their study. Especially since many prospective randomized study protocols, therefore of superior quality to this observational study, are still in progress.
" We were unable to confirm a benefit of hydroxychloroquine or chloroquine (...) on the prognosis of hospitalized Covid-19 patients ", they write. "Each of these protocols, when used for the treatment of Covid-19, was associated with decreased survival in hospital and
This article is for subscribers only. You still have 59% to discover.
Subscribe: € 1 the first month
cancellable at any timeEnter your email
Already subscribed? Log in